Overview

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Status:
RECRUITING
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The current study aims to explore the potential advantages of anti-cancer therapy that is implemented based on drug sensitivity testing. This pertains to individuals with locally advanced thyroid cancer who have undergone conventional therapy in the past or unresectable patients .
Phase:
PHASE2
Details
Lead Sponsor:
West China Hospital
Treatments:
anlotinib
apatinib
cabozantinib
dabrafenib
donafenib
entrectinib
Everolimus
larotrectinib
lenvatinib
pralsetinib
Sorafenib
trametinib
vandetanib